<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00441012</url>
  </required_header>
  <id_info>
    <org_study_id>V121-019</org_study_id>
    <secondary_id>2007_513</secondary_id>
    <nct_id>NCT00441012</nct_id>
  </id_info>
  <brief_title>Study of Modified Process Hib/Hep B Vaccine in Infants (V121-019)(COMPLETED)</brief_title>
  <official_title>A Study in Healthy Infants of the Safety, Tolerability, and Immunogenicity of Haemophilus Influenzae, Type b/Hepatitis B Vaccine Manufactured With a Modified Process</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      To determine if there is an improvement in the immune response to HBsAg (hepatitis B virus)
      in healthy infants using a modified process in a combination Haemophilus Influenzae, type
      b/Hepatitis B vaccine and a currently licensed Haemophilus Influenzae, type b/Hepatitis B
      vaccine
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Anti-HBs Seroprotected Participants 1 Month After the Third Dose.</measure>
    <time_frame>11 months (1 month after the third dose)</time_frame>
    <description>The number of participants as measured by the seroprotection rate (anti-hepatitis B surface antibodies greater than or equal to 10 mIU/mL). Anti-HBs (Antibodies against hepatitis B surface antigen) titers were measured from blood samples taken at Month 11 (1 month after the third dose)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Anti-HBs GMT (Geometric Mean Titer) 1 Month After the Third Dose.</measure>
    <time_frame>11 months (1 month after the third dose)</time_frame>
    <description>Geometric Mean Titer (GMT) - This is an Antibody titer that is measured using a laboratory test to detect the presence and amount of antibodies in a person's blood. Anti-HBs (Antibodies against hepatitis B surface antigen) and Geometric Mean Titers were measured from blood samples taken at Month 11 (1 month after the third dose).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Total Number of Participants With Serious Vaccine-Related Clinical Adverse Experiences</measure>
    <time_frame>0-11 months (recorded from first dose until the participant completes or discontinues)</time_frame>
    <description>Participants with adverse experiences considered possibly, probably, or definitely related to study vaccines and considered serious (death, persistent disability, life threatening, hospitalization, birth defects, cancer, or overdose)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Anti-PRP Seroprotected Participants 1 Month After the Third Dose.</measure>
    <time_frame>11 months (1 month after the third dose)</time_frame>
    <description>The number of participants as measured by the seroprotection rate (anti-polyribosylribitol phosphate antibodies greater than 1 µg/mL). Anti-PRP (Antibodies against polyribosylribitol phosphate) titers were measured from blood samples taken at Month 11 (1 month after
the third dose)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Anti-PRP GMT (Geometric Mean Titer) 1 Month After the Third Dose.</measure>
    <time_frame>11 months (1 month after the third dose)</time_frame>
    <description>Geometric Mean Titer (GMT) - This is an Antibody titer that is measured using a laboratory test to detect the presence and amount of antibodies in a person's blood. Anti-PRP (Antibodies against polyribosylribitol phosphate) titers were measured from blood samples taken at Month 11 (1 month after the third dose)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">546</enrollment>
  <condition>Haemophilus Influenzae Type B</condition>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Modified process Hib/Hep B vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>COMVAX™</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: Modified Process Vaccine</intervention_name>
    <description>Modified process vaccine HBsAg 5 ug/0.5 mL and PRP [OMPC] 7.5 ug/0.5 mL in a 3-dose regimen at 2, 4 &amp; 12 months of age. Duration of treatment is 11 months.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: COMVAX™</intervention_name>
    <description>COMVAX™ HBsAg 5 ug/0.5 mL and PRP [OMPC] 7.5 ug/0.5 mL in a 3-dose regimen at 2, 4, and 12 months of age. Duration of treatment is 11 months.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy 2-month-old full term infants born to non-HBs Ag (hepatitis B virus) carrier
             mothers

        Exclusion Criteria:

          -  Birth mother known to be a carrier of hepatitis B virus (HBsAg+) or known carriers
             ever living in close contact with the subject

          -  History of previous hepatitis B infection; history of vaccination with any hepatitis B
             vaccine

          -  Recent (&lt;72 hours) history of febrile illness (rectal temperature &gt;=38.1°C/&gt;=100.5°F)

          -  Known or suspected hypersensitivity to any component of RECOMBIVAXHB™ or COMVAX™
             (e.g., aluminum, yeast)

          -  Recent administration (w/i 3 months prior to study start) of hepatitis B immune
             globulin (HBIg), serum immune globulin, or any other blood-derived product

          -  Receipt of investigational drugs or investigational vaccines within 3 months prior to
             study start or if planned within the study period;

          -  Known or suspected impairment of immunologic function or recent use (within 3 months
             prior to study start) of immunomodulatory medications (does not include topical and
             inhaled steroids);

          -  Any condition that, in the opinion of the investigator, might interfere with the
             evaluation of study objectives; or inability to comply with the study schedule and/or
             inability to attend all required study visits
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Days</minimum_age>
    <maximum_age>80 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>Finland</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>MedWatch - FDA maintained medical product safety Information</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>Merck: Patient &amp; Caregiver U.S. Product Web Site</description>
  </link>
  <results_reference>
    <citation>Lee AW, Vesikari T, Gilbert CL, Klopfer SO, Schödel FP, Bhuyan PK. Immunogenicity and safety of a Haemophilus influenzae B (Hib)-hepatitis B vaccine with a modified process hepatitis B component administered with concomitant pneumococcal conjugate vaccine to infants. Vaccine. 2011 Oct 19;29(45):7942-8. doi: 10.1016/j.vaccine.2011.08.071. Epub 2011 Aug 27.</citation>
    <PMID>21875633</PMID>
  </results_reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2007</study_first_submitted>
  <study_first_submitted_qc>February 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2007</study_first_posted>
  <results_first_submitted>May 11, 2009</results_first_submitted>
  <results_first_submitted_qc>May 19, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 10, 2009</results_first_posted>
  <last_update_submitted>March 2, 2015</last_update_submitted>
  <last_update_submitted_qc>March 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Haemophilus Influenza, type b and Hepatitis B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>06-Dec-2006 (First Participant Enrolled in Study) to 03-Jun-2008 (Last Participant had their Last Visit).
This study was conducted at 27 sites: 17 in Canada (16 of which were active sites) and 10 in Finland.</recruitment_details>
      <pre_assignment_details>Participants excluded for history of or prior vaccination for hepatitis B (Hep B) or Haemophilus influenzae Type B (Hib) disease and for administration of blood products. Participants also excluded if mother received Hep B, Hib vaccine, or blood products 6 months prior to participant birth.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Modified Process Vaccine</title>
          <description>Modified Process Vaccine (0, 2, and 10 months), 5/7.5 µg (micrograms)</description>
        </group>
        <group group_id="P2">
          <title>COMVAX™</title>
          <description>COMVAX™ (0, 2, and 10 months), 5/7.5 µg (micrograms)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="270"/>
                <participants group_id="P2" count="276"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination Visit 1</title>
              <participants_list>
                <participants group_id="P1" count="269">1 participant was randomized but not vaccinated in the Modified Process Vaccine group</participants>
                <participants group_id="P2" count="276">3 participants were vaccinated but were never randomized in the COMVAX™ group</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination Visit 2</title>
              <participants_list>
                <participants group_id="P1" count="267"/>
                <participants group_id="P2" count="272"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination Visit 3</title>
              <participants_list>
                <participants group_id="P1" count="265"/>
                <participants group_id="P2" count="269"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="252"/>
                <participants group_id="P2" count="263"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Randomized but Not Vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Modified Process Vaccine</title>
          <description>Modified Process Vaccine (0, 2, and 10 months), 5/7.5 µg (micrograms)
1 participant randomized but not vaccinated in the Modified Process Vaccine group; overall N is 269, not 270.</description>
        </group>
        <group group_id="B2">
          <title>COMVAX™</title>
          <description>COMVAX™ (0, 2, and 10 months), 5/7.5 µg (micrograms)
3 participants in the COMVAX™ group vaccinated but not randomized; overall N is 276, not 273 - due to issues randomizing via IVRS, in violation, all 3 participants were vaccinated as randomly assigned by the Investigator.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="269"/>
            <count group_id="B2" value="276"/>
            <count group_id="B3" value="545"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.7" spread="8.9"/>
                    <measurement group_id="B2" value="68.3" spread="8.5"/>
                    <measurement group_id="B3" value="68.0" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.7" lower_limit="41" upper_limit="82"/>
                    <measurement group_id="B2" value="68.3" lower_limit="40" upper_limit="83"/>
                    <measurement group_id="B3" value="68.0" lower_limit="40" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Anti-HBs Seroprotected Participants 1 Month After the Third Dose.</title>
        <description>The number of participants as measured by the seroprotection rate (anti-hepatitis B surface antibodies greater than or equal to 10 mIU/mL). Anti-HBs (Antibodies against hepatitis B surface antigen) titers were measured from blood samples taken at Month 11 (1 month after the third dose)</description>
        <time_frame>11 months (1 month after the third dose)</time_frame>
        <population>Per-Protocol Population: The Per-Protocol Population is defined as the participants that were able to complete the study as defined by the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Modified Process Vaccine</title>
            <description>Modified Process Vaccine (0, 2, and 10 months), 5/7.5 µg (micrograms)</description>
          </group>
          <group group_id="O2">
            <title>COMVAX™</title>
            <description>COMVAX™ (0, 2, and 10 months), 5/7.5 µg (micrograms)</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Anti-HBs Seroprotected Participants 1 Month After the Third Dose.</title>
          <description>The number of participants as measured by the seroprotection rate (anti-hepatitis B surface antibodies greater than or equal to 10 mIU/mL). Anti-HBs (Antibodies against hepatitis B surface antigen) titers were measured from blood samples taken at Month 11 (1 month after the third dose)</description>
          <population>Per-Protocol Population: The Per-Protocol Population is defined as the participants that were able to complete the study as defined by the protocol.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="228"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="230"/>
                    <measurement group_id="O2" value="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The purpose of the primary analysis is to demonstrate that there is an adequate seroprotection rate (percentage of participants with anti-HBs &gt;=10mIU/mL) in each group at 1 month after the third dose. An adequate response requires the lower bound of the two-sided 95% confidence interval for the seroprotection rate to exceed 90%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of Seroprotected Participants</param_type>
            <param_value>100</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>98.7</ci_lower_limit>
            <ci_upper_limit>100.0</ci_upper_limit>
            <estimate_desc>Exact binomial confidence interval</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The purpose of the primary analysis is to demonstrate that there is an adequate seroprotection rate (percentage of participants with anti-HBs &gt;=10mIU/mL) in each group at 1 month after the third dose. An adequate response requires the lower bound of the two-sided 95% confidence interval for the seroprotection rate to exceed 90%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of Seroprotected Participants</param_type>
            <param_value>99.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>69.9</ci_lower_limit>
            <ci_upper_limit>99.9</ci_upper_limit>
            <estimate_desc>Exact binomial confidence interval</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Anti-HBs GMT (Geometric Mean Titer) 1 Month After the Third Dose.</title>
        <description>Geometric Mean Titer (GMT) – This is an Antibody titer that is measured using a laboratory test to detect the presence and amount of antibodies in a person's blood. Anti-HBs (Antibodies against hepatitis B surface antigen) and Geometric Mean Titers were measured from blood samples taken at Month 11 (1 month after the third dose).</description>
        <time_frame>11 months (1 month after the third dose)</time_frame>
        <population>Per-Protocol Population: The Per-Protocol Population is defined as the participants that were able to complete the study as defined by the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Modified Process Vaccine</title>
            <description>Modified Process Vaccine (0, 2, and 10 months), 5/7.5 µg (micrograms)</description>
          </group>
          <group group_id="O2">
            <title>COMVAX™</title>
            <description>COMVAX™ (0, 2, and 10 months), 5/7.5 µg (micrograms)</description>
          </group>
        </group_list>
        <measure>
          <title>The Anti-HBs GMT (Geometric Mean Titer) 1 Month After the Third Dose.</title>
          <description>Geometric Mean Titer (GMT) – This is an Antibody titer that is measured using a laboratory test to detect the presence and amount of antibodies in a person's blood. Anti-HBs (Antibodies against hepatitis B surface antigen) and Geometric Mean Titers were measured from blood samples taken at Month 11 (1 month after the third dose).</description>
          <population>Per-Protocol Population: The Per-Protocol Population is defined as the participants that were able to complete the study as defined by the protocol.</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="228"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4204.4" lower_limit="3411.2" upper_limit="5182.0"/>
                    <measurement group_id="O2" value="1683.4" lower_limit="1350.4" upper_limit="2098.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The Modified Process Vaccine is non-inferior to COMVAX with respect to anti-HBs GMT. The non-inferiority criterion requires that the lower bound of the two-sided 95% confidence interval on the ratio of the Month 11 GMTs [GMT modified process vaccine/GMT COMVAX™] is &gt;0.67.</non_inferiority_desc>
            <param_type>Geometric Mean Titer Ratio</param_type>
            <param_value>2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.9</ci_lower_limit>
            <ci_upper_limit>3.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Total Number of Participants With Serious Vaccine-Related Clinical Adverse Experiences</title>
        <description>Participants with adverse experiences considered possibly, probably, or definitely related to study vaccines and considered serious (death, persistent disability, life threatening, hospitalization, birth defects, cancer, or overdose)</description>
        <time_frame>0-11 months (recorded from first dose until the participant completes or discontinues)</time_frame>
        <population>Safety Analysis Set: The Safety Analysis Set is defined as all participants who receive at least one injection of vaccine and who had a safety follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Modified Process Vaccine</title>
            <description>Modified Process Vaccine (0, 2, and 10 months), 5/7.5 µg (micrograms)</description>
          </group>
          <group group_id="O2">
            <title>COMVAX™</title>
            <description>COMVAX™ (0, 2, and 10 months), 5/7.5 µg (micrograms)</description>
          </group>
        </group_list>
        <measure>
          <title>The Total Number of Participants With Serious Vaccine-Related Clinical Adverse Experiences</title>
          <description>Participants with adverse experiences considered possibly, probably, or definitely related to study vaccines and considered serious (death, persistent disability, life threatening, hospitalization, birth defects, cancer, or overdose)</description>
          <population>Safety Analysis Set: The Safety Analysis Set is defined as all participants who receive at least one injection of vaccine and who had a safety follow-up.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
                <count group_id="O2" value="273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Anti-PRP Seroprotected Participants 1 Month After the Third Dose.</title>
        <description>The number of participants as measured by the seroprotection rate (anti-polyribosylribitol phosphate antibodies greater than 1 µg/mL). Anti-PRP (Antibodies against polyribosylribitol phosphate) titers were measured from blood samples taken at Month 11 (1 month after
the third dose)</description>
        <time_frame>11 months (1 month after the third dose)</time_frame>
        <population>Per-Protocol Population: The Per-Protocol Population is defined as the participants that were able to complete the study as defined by the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Modified Process Vaccine</title>
            <description>Modified Process Vaccine (0, 2, and 10 months), 5/7.5 µg (micrograms)</description>
          </group>
          <group group_id="O2">
            <title>COMVAX™</title>
            <description>COMVAX™ (0, 2, and 10 months), 5/7.5 µg (micrograms)</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Anti-PRP Seroprotected Participants 1 Month After the Third Dose.</title>
          <description>The number of participants as measured by the seroprotection rate (anti-polyribosylribitol phosphate antibodies greater than 1 µg/mL). Anti-PRP (Antibodies against polyribosylribitol phosphate) titers were measured from blood samples taken at Month 11 (1 month after
the third dose)</description>
          <population>Per-Protocol Population: The Per-Protocol Population is defined as the participants that were able to complete the study as defined by the protocol.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="228"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216"/>
                    <measurement group_id="O2" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of Seroprotected Participants</param_type>
            <param_value>93.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>90.0</ci_lower_limit>
            <ci_upper_limit>96.6</ci_upper_limit>
            <estimate_desc>Exact binomial confidence interval</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No hypothesis is being tested. The purpose of the secondary analysis is to estimate the seroprotection rate (percentage of participants with anti-PRP &gt; 1µg/mL) in each group at 1 month after the third dose.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of Seroprotected Participants</param_type>
            <param_value>92.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>87.8</ci_lower_limit>
            <ci_upper_limit>95.3</ci_upper_limit>
            <estimate_desc>Exact binomial confidence interval</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Anti-PRP GMT (Geometric Mean Titer) 1 Month After the Third Dose.</title>
        <description>Geometric Mean Titer (GMT) – This is an Antibody titer that is measured using a laboratory test to detect the presence and amount of antibodies in a person's blood. Anti-PRP (Antibodies against polyribosylribitol phosphate) titers were measured from blood samples taken at Month 11 (1 month after the third dose)</description>
        <time_frame>11 months (1 month after the third dose)</time_frame>
        <population>Per-Protocol Population: The Per-Protocol Population is defined as the participants that were able to complete the study as defined by the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Modified Process Vaccine</title>
            <description>Modified Process Vaccine (0, 2, and 10 months), 5/7.5 µg (micrograms)</description>
          </group>
          <group group_id="O2">
            <title>COMVAX™</title>
            <description>COMVAX™ (0, 2, and 10 months), 5/7.5 µg (micrograms)</description>
          </group>
        </group_list>
        <measure>
          <title>The Anti-PRP GMT (Geometric Mean Titer) 1 Month After the Third Dose.</title>
          <description>Geometric Mean Titer (GMT) – This is an Antibody titer that is measured using a laboratory test to detect the presence and amount of antibodies in a person's blood. Anti-PRP (Antibodies against polyribosylribitol phosphate) titers were measured from blood samples taken at Month 11 (1 month after the third dose)</description>
          <population>Per-Protocol Population: The Per-Protocol Population is defined as the participants that were able to complete the study as defined by the protocol.</population>
          <units>µg /mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="228"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="6.0" upper_limit="8.4"/>
                    <measurement group_id="O2" value="8.0" lower_limit="6.7" upper_limit="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Modified Process Vaccine</title>
          <description>Modified Process Vaccine (0, 2, and 10 months), 5/7.5 µg (micrograms)</description>
        </group>
        <group group_id="E2">
          <title>COMVAX™</title>
          <description>COMVAX™ (0, 2, and 10 months), 5/7.5 µg (micrograms)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0"/>
                <counts group_id="E2" subjects_affected="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Medication error</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="259"/>
                <counts group_id="E2" subjects_affected="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Regurgitation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Teething</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="131" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="162" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="167" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="174" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="179" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Injection site hematoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Injection site nodule</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="195" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="213" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="164" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="146" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

